Adicet Bio Q1 2024 net loss $28.0M; on track for lupus nephritis trial and ADI-270 IND

Adicet Bio, Inc.

2024-Q1 EPS reported -$0.35

Net loss of $28.0M ($0.35 per share) vs $30.9M ($0.72 per share) in Q1 2023.
Cash and equivalents $247.6M as of March 31, 2024; expected runway into H2 2026.
On track to initiate Phase 1 of ADI-001 in lupus nephritis in Q2 2024; data expected Q4 2024 or Q1 2025.
Preclinical data for ADI-270 presented at ASGCT; IND for renal cell carcinoma planned Q2 2024.
Enrolling MCL patients in ADI-001 GLEAN study; clinical update with 6-month data expected H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Adicet Bio, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $28.0 million, EPS $0.35 per basic and diluted share.

Period: first quarter ended March 31, 2024
Net income: net loss of $28.0 million
EPS: $0.35 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2024 was $28.0 million, or a net loss of $0.35 per basic and diluted share

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.